N,N-dimethyl-2,3-didodecyloxypropylamine | 848982-36-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N-dimethyl-2,3-didodecyloxypropylamine
• 英文别名: (rac)-2,3-bis(dodecyloxy)-N,N-dimethyl-propanamine；2,3-didodecoxy-N,N-dimethylpropan-1-amine
• CAS: 848982-36-5
• 化学式: C₂₉H₆₁NO₂
• 分子量: 455.809
• InChiKey: IUAUYSMYFCQVNW-UHFFFAOYSA-N

物化性质

• 沸点：
  517.9±35.0 °C(Predicted)
• 密度：
  0.863±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.2
• 重原子数：
  32
• 可旋转键数：
  27
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N,N-dimethyl-2,3-didodecyloxypropylamine 在 肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 168.0h， 生成 (rac)-N-(3-aminopropyl)-2,3-bis(dodecyloxy)-N,N-dimethyl-1-propanaminium bromide
  参考文献：
  名称：

  Lipid Compounds Targeting VLA-4

  摘要：

  这项发明涉及公式I的化合物： 以及其药用可接受的盐和酯，其中n、G、W、X、Y和R1在详细说明和索赔中有定义。公式I的化合物与VLA-4结合或与之相关，并可用于传递制剂，将药物、核酸或其他治疗化合物传递到表达VLA-4的组织或细胞中。

  公开号：

  US20130079383A1
• 作为产物：
  描述：

  十二烷醇 在 sodium hydride 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 146.08h， 生成 N,N-dimethyl-2,3-didodecyloxypropylamine
  参考文献：
  名称：

  Lipid Compounds Targeting VLA-4

  摘要：

  这项发明涉及公式I的化合物： 以及其药用可接受的盐和酯，其中n、G、W、X、Y和R1在详细说明和索赔中有定义。公式I的化合物与VLA-4结合或与之相关，并可用于传递制剂，将药物、核酸或其他治疗化合物传递到表达VLA-4的组织或细胞中。

  公开号：

  US20130079383A1

文献信息

• Synthesis, characterization and transfection activity of new saturated and unsaturated cationic lipids
  作者：Silvia Arpicco、Silvana Canevari、Maurizio Ceruti、Enrico Galmozzi、Flavio Rocco、Luigi Cattel

  DOI：10.1016/j.farmac.2004.06.007

  日期：2004.11

  We synthesized new cationic lipids, analogue to N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) and 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide (DMRIE), in order to compare those containing a dodecyl chain with those having a relatively long chain with two or five double bonds, such as squalenyl and dihydrofarnesyl derivatives, or complex saturated structures, such as squalane derivatives. The fusogenic helper lipid dioleoylphosphatidylethanolamine (DOPE) was added to cationic lipids to form a stable complex. Liposomes composed of 50:50 w/w cationic lipid/DOPE were prepared and incubated with plasmidic DNA at various charge ratios and the diameter and zeta potential of the complexes were measured. The surface charge of the DNA/lipid complexes can be controlled by adjusting the cationic lipid/DNA ratio. Finally, we tested the in vitro transfection efficiency of the cationic lipid/DNA complexes using different cell lines. The transfection efficiency was highest for the dodecyloxy derivative containing a single hydroxyethyl group in the head, followed by the dodecyloxy and the farnesyloxy trimethylammonium derivatives. Instead the C27 squalenyl and C27 squalanyl derivatives resulted inactive.
• Interaction of doxorubicin hydrochloride in the presence of, mixed aggregate of ibuprofen sodium and cationic lipid
  作者：Guanyi Li、Anirudh Srivastava、Chenyu Liu、Weihong Qiao

  DOI：10.1016/j.molliq.2020.113451

  日期：2020.9

  This research was highlighted the importance of mixed aggregates based on drug-lipid to improve the interaction of one or more drugs in aqueous medium. This mixed aggregate can significantly inhibit the growth of MCF-7 cells, and has great potential for anti-inflammatory and cancer treatment after tumor removal. The cationic lipid (CL) has been synthesized with multistep reaction and is characterized by H-1 NMR and mass spectroscopy. CL and ibuprofen (IBF) physiochemical analysis was investigated using surface tension, conductance, dynamic light scattering (DLS), and electron microscope transmission (TEM). The strong synergism between mixed aggregate (UB) system CL and IBF was observed. The study on UV spectroscopy measured that the LIB mixed aggregate showed optimum binding to doxorubicin hydrochloride (DOX) and the binding constant Log K-b was 6.17 compared to single CL, the Log K-b was 5.83. Binding results indicated that the DOX was more encapsulated in mixed LIB aggregates compared to single CL aggregates. This mixed aggregate LIB has excellent performance in controlling the release of drugs. For single CL aggregate, approximately 62.5% DOX was released after 72 h (pH - 7.4). However, LIB such as, (0.1 alpha(CL)+ 0.9 alpha(IBF)), the release of DOX decreased to 16.08%. Finally. LIB mixed aggregate applicability has been used to minimize the cytotoxicity of MCF-7 cells, and it has been found that DOX in UB mixed aggregates has a higher inhibitory effect on cell growth than DOX in CL. (C) 2020 Elsevier B.V. All rights reserved.
• WO2008/148057
  申请人：——

  公开号：——

  公开（公告）日：——
• Lipid Compounds Targeting VLA-4
  申请人：BOYLAN John Frederick

  公开号：US20130079383A1

  公开（公告）日：2013-03-28

  The invention relates to the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.

  这项发明涉及公式I的化合物： 以及其药用可接受的盐和酯，其中n、G、W、X、Y和R1在详细说明和索赔中有定义。公式I的化合物与VLA-4结合或与之相关，并可用于传递制剂，将药物、核酸或其他治疗化合物传递到表达VLA-4的组织或细胞中。